Beyond Biotech - the podcast from Labiotech

Beyond Biotech podcast 26: CellCentric, MicrofluidX, Potter Clarkson

December 16, 2022 Labiotech
Beyond Biotech - the podcast from Labiotech
Beyond Biotech podcast 26: CellCentric, MicrofluidX, Potter Clarkson
Show Notes

2:19 news
4:37 CellCentric
12:21 MicrofluidX
29:12 Potter Clarkson

This week, we have three guests. We have conversations with Antoine Espinet, CEO of MicrofluidX; Will West, CEO of CellCentric; and Sara Holland, patent attorney at Potter Clarkson.

MicrofluidX raises £3.3M to develop advanced therapy manufacturing platform

MicrofluidX (MFX), a U.K. based provider of next-generation bioreactors for cell research and manufacturing, today announces £3.3 million ($4 million) of secured investments, bringing the company’s total funding to date to £7 million ($8.5 million). 

MFX’s next generation platform, the Cyto Engine, addresses the need for an affordable, scalable cell culture platform to revolutionize research, facilitate large-scale manufacture, and enable widespread access to advanced therapies.  

“Advanced therapy manufacturing is hindered by out of date, inadequate manufacturing technologies,” said Antoine Espinet, CEO of MFX. 

“Our aim to commoditize manufacturing for cell and gene therapies through automation, digitalization, and the adoption of machine learning is supported by our investors, who appreciate the incredible impact this could have on the cell and gene therapy sector, and ultimately patients around the world.”

MFX said it is addressing the two large pain points faced by the advanced therapies industry, commercialization and clinical translation. 

By providing a scalable bioprocessing platform with complete integration of online process analytical tools and data analytics powered by machine learning, the company hopes the Cyto Engine will reduce the cost and time of advanced therapy development and help bring these life-saving treatments to patients. 

Potter Clarkson patent attorney, Sara Holland

Sara Holland is a former research scientist turned patent attorney in the U.K. 

After finishing her PhD in engineering artificial yeast chromosomes, Holland carried out seven years of postdoctoral research at the University of Nottingham. This gave her a good understanding of the challenges that scientists face when she moved over to Potter Clarkson, an IP law firm.

In her work as a patent attorney she helps universities, technology transfer departments and SMEs protect their inventions, with a focus on synthetic biology.

Holland also co-founded the Women in Synthetic Biology Network, a group that aims to support gender diversity and support women working in the field of synthetic biology.

CellCentric presents early clinical data at ASH

 CellCentric, a clinical stage biotechnology company pioneering small molecule inhibition of p300/CBP to treat cancer, announced clinical data for the first time at the 64th American Society of Haematology (ASH) annual meeting in New Orleans. 

To date, 26 patients with relapsed/refractory multiple myeloma (RRMM) have been treated with inobrodib as monotherapy, including seven most recently at the recommended phase 2 dose and dose schedule (RP2D). Treatment has been generally well-tolerated with the majority of on-target toxicities being mild or moderate in severity. 

Among the patients treated at the RP2D, six out of seven patients had reduction or stabilization of serum free light chains. One patient saw an unconfirmed complete response (CR), which went on to become a durable confirmed very good partial response (VGPR); a second patient demonstrated a confirmed partial response (PR); and a third currently has an unconfirmed PR (by IMWG response criteria).  These three patients remain on treatment after more than eight months.